Acyclovir (CID 2022) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(421)
 
 
Inactive(1291)
 
 
Inconclusive(151)
 
 
Unspecified(1417)
 
 
Top Targets:
7TM GPCR Srx(36)
 
 
 
p450(31)
 
 
 
7TM GPCR Srsx(22)
 
 
 
HELICc(15)
 
 
 
 
Tryp SPc(14)
 
 
 
BioAssay Types:
Literature(1811)
 
 
 
 
 
Confirmatory(594)
 
 
 
 
 
Screening(556)
 
 
 
 
 
Summary(1)
 
 
BioActivity Types:
Potency(480)
 
 
 
 
 
EC50(349)
 
 
 
 
 
IC50(338)
 
 
 
 
 
Ki(1)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 2889    Data Row: 3280   Total Pages: 66   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103504725]
MIC 0.01Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (Brand) in vero cells [AID87969, Type: Literature]
View
2
[SID103504725]
EC50 0.011Antiviral activity against HSV1 PAA5 harboring polymerase R842S mutant gene infected in HFF after 3 days by plaque reduction assay [AID563769, Type: Literature]
View
3
[SID103504725]
EC50 0.02Effective concentration to inhibit 50% of hepatitis B virus replication in a cell culture model [AID246328, Type: Literature]
View
4
[SID103504725]
EC50 0.03Inhibition of VZV replication in HFF cells by cytopathic effect assay [AID273052, Type: Literature]
View
5
[SID103504725]
ED50 0.04Concentration of compound required to reduce by 50% the number of herpes simplex virus (HSV-1) plaques in vero cells [AID217580, Type: Literature]
View
6
[SID103504725]
EC50 0.04Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells [AID91297, Type: Literature]
View
7
[SID103504725]
EC50 0.08Antiviral activity against HSV1 E377 infected in HFF after 3 days by plaque reduction assay [AID563746, Type: Literature]
View
8
[SID103504725]
EC50 0.09Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells [AID91299, Type: Literature]
View
9
[SID103504725]
IC50 0.1The concentration required to inhibit the growth of viral plaques by 50% of control in plaque reduction assay [AID217745, Type: Literature]
View
10
[SID103504725]
IC50 0.1The compound was tested for plaque inhibition in HSV-1 in cell culture, activity is determined by plaque reduction assay [AID85708, Type: Literature]
View
11
[SID103504725]
IC50 0.11Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (KOS) in HeLa cell culture [AID86969, Type: Literature]
View
12
[SID103504725]
EC50 0.16Antiviral activity against HSV-1 (herpes simplex virus) [AID85886, Type: Literature]
View
13
[SID103504725]
IC50 0.16The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain [AID81026, Type: Literature]
View
14
[SID103504725]
EC50 0.16Antiviral activity against HSV1 KOS infected in HEL assessed as reduction in virus-induce cytopathicity [AID516965, Type: Literature]
View
15
[SID103504725]
IC50 0.19Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (G) in HeLa cell culture [AID86844, Type: Literature]
View
16
[SID103504725]
IC50 0.2Antiviral activity against against herpes simplex virus-1. [AID84070, Type: other]
View
17
[SID103504725]
ID50 0.2Anti viral activity against HSV-1(Schooler) in WI-38 cell monolayers [AID218417, Type: Literature]
View
18
[SID103504725]
ED50 0.2Effective dose required to inhibit cell growth against HSV-1 (schooler); Value ranges from 0.2-0.4 [AID87483, Type: other]
View
19
[SID103504725]
EC50 0.2Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect [AID569233, Type: Literature]
View
20
[SID103504725]
EC50 0.2Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs [AID342115, Type: Literature]
View
21
[SID103504725]
EC50 0.2Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity [AID431628, Type: Literature]
View
22
[SID103504725]
EC50 0.2Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days [AID658617, Type: Literature]
View
23
[SID103504725]
EC50 0.23Antiviral activity against Herpes simplex virus 2 strain G assessed as reduction of virus induced cytopathicity by cell based assay [AID609575, Type: Literature]
View
24
[SID103504725]
EC50 0.23Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity [AID611617, Type: Literature]
View
25
[SID103504725]
MIC 0.242Minimum inhibitory concentration against Herpes simplex Virus-2(G) [AID87031, Type: Literature]
View
26
[SID855732]
Potency 0.2593qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
27
[SID855732]
Potency 0.2593qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
28
[SID855732]
Potency 0.2593qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
29
[SID103504725]
EC50 0.27Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity [AID611615, Type: Literature]
View
30
[SID103504725]
EC50 0.3Antiviral activity against Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay [AID609574, Type: Literature]
View
31
[SID103504725]
IC50 0.3Antiviral activity against HSV1 by plaque reduction assay [AID589394, Type: Literature]
View
32
[SID103504725]
EC50 0.3Antiviral activity against Herpes simplex virus type 1 in african green monkey BSC1 cells by plaque reduction assay [AID419662, Type: Literature]
View
33
[SID103504725]
EC50 0.3Antiviral activity against acyclovir-resistant HSV2 strain G infected in HEL assessed as reduction in virus-induce cytopathicity [AID516967, Type: Literature]
View
34
[SID103504725]
IC50 0.32Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay [AID412418, Type: Literature]
View
35
[SID103504725]
EC50 0.32Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells [AID82686, Type: Literature]
View
36
[SID103504725]
EC50 0.32Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells [AID246376, Type: Literature]
View
37
[SID103504725]
EC50 0.33Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA [AID273048, Type: Literature]
View
38
[SID103504725]
MIC 0.341Minimum inhibitory concentration against Herpes simplex Virus-1(F) [AID87025, Type: Literature]
View
39
[SID103504725]
MIC 0.341Minimum inhibitory concentration against Herpes simplex Virus-1(KOS) [AID87026, Type: Literature]
View
40
[SID103504725]
MIC 0.341Minimum inhibitory concentration against Herpes simplex Virus-1 (McIntyre) [AID87028, Type: Literature]
View
41
[SID103504725]
EC50 0.36Antiviral activity against Herpes simplex virus type-1 (HSV-1). [AID87479, Type: Literature]
View
42
[SID103504725]
EC50 0.38Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay [AID675215, Type: Literature]
View
43
[SID103504725]
IC50 0.384Antiviral activity against Vaccinia virus [AID392536, Type: Literature]
View
44
[SID103504725]
IC50 0.39Antiviral activity against HSV1 SC16 in Vero cells by capture hybrid method [AID290509, Type: Literature]
View
45
[SID103504725]
IC50 0.39Antiviral activity against HSV1 SC16 in african green monkey Vero cells [AID313908, Type: Literature]
View
46
[SID103504725]
IC50 0.39Antiviral activity against HSV1 SC16 infected in african green monkey Vero cells by hybrid capture method [AID447282, Type: Literature]
View
47
[SID103504725]
EC50 0.4Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect [AID569231, Type: Literature]
View
48
[SID103504725]
EC50 0.4Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity [AID431627, Type: Literature]
View
49
[SID103504725]
MIC 0.4Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity [AID297314, Type: Literature]
View
50
[SID103504725]
MIC 0.4Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity [AID297315, Type: Literature]
View